Search Results

21 - 30 of 44 items :

  • pharmacokinetics x
  • Life Sciences x
  • Clinical Medicine x
Clear All
Advances in Studies Related to Interleukin-12 Family and Infectious Diseases

. Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virol Sin, 2013,28(3): 167-173. 10 Metzger DW. Interleukin-12 as an adjuvant for induction of protective antibody responses. Cytokine, 2010, 52(1-2):102-107. 11 Wei F, Wang H, Zhang J, et al . Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. J Exp Clin Cancer Res, 2013,32:5. 12 Saghafian-Hedengren S, Sohlberg E, Theorell J, et al . Epstein-Barr virus coinfection in children boosts

Open access
Health-promoting properties of compounds derived from Capsicum sp. A review

450 isozyme activities. Drug Metab Dispos 2016; pii: dmd.116.073213. doi: 86. Zhai XJ, Chen JG, Liu JM, Shi F, Lu YN. Food-drug interactions: effect of capsaicin on the pharmacokinetics of simvastatin and its active metabolite in rats. Food Chem Toxicol 2013; 53:168-173. doi: 87. Zhu C, Zhai X, Chen F, Wang N, Zhang X, Lu Y. Capsaicin induces metabolism of simvasatin in rat: involvement of upregulating expression of Ugt1a1. Pharmazie 2016; 71

Open access
Immune response of mice to Echinococcus multilocularis infection after therapy with amphotericin B colloidal dispersion

. Vet. J., 165: 266–275 [9] Christiansen, K. J., Bernard, E. M., Gold, J. W. M., Armstrong, D. (1985): Distribution and activity of amphotericin B in humans. J. Infect. Dis., 152: 1037–1043 [10] Clements, J. S. Jr., Peacock, J. E. Jr. (1990): Amphotericin B revisited: reassessment of toxicity. Amer. J. Med., 88: 22–27 [11] Clemons, K. V., Sobel, R. A., Williams, P. L., Stevens, D. A. (2001): Comparative toxicities and pharmacokinetics of

Open access
Psychoactive plants used in designer drugs as a threat to public health

, Valle M, Urbano G, yritia M, Morte A, Barbanoj MJ. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 2003; 306(1):73-83. 76. Osmond H. Ololiuqui: the ancient Aztec narcotic remarks on the effects of Rivea corymbosa (Ololiuqui). J Ment Sci 1955; 101 (424):526-537. 77. Piekoszewski W, Florek E. Dopalacze. Przegl Lek 2009; 66(10):861-865. 78. Rech MA, Donahey E, Cappiello Dziedzic JM, Oh L, Greenhalgh E. New drugs of abuse

Open access
Research progress on anti-infection therapy for sepsis in children

, and other factors of the current, local, hospital, department, and use empirical antimicrobial agents early [ 24 ]. Moreover, whether the case is hospital-acquired or out-of-hospital infection should be determined, and the presence of a clear focus of infection should be known. The selected drug should be a wide spectrum of antimicrobial agent that covers possible pathogenic microorganisms (bacterial or fungal) and has good penetration in the likely infected tissue. The pharmacokinetics of the antimicrobials will change significantly during the course of treatment

Open access
Anthelmintic resistance in parasites of small ruminants: sheep versus goats

)90059-0 [31] Hennessy, D. R., Sangster, N. C., Steel, J. W., Collins, G. H. (1993): Comparative pharmacokinetic behaviour of albendazole in sheep and goats. Int. J. Parasitol., 23: 321–325. DOI: 10.1016/0020-7519(93)90006-K [32] Hertzberg H., Bauer C. (2000): Anthelminthika-Resistenzen bei Magen-Darm Strongyliden von Schafen und Ziegen: Aktuelles ueber Verbreitung, Epidemiologie, Vorbeugemaßnahmen und Alternativen zum Anthelminthika- Einsatz. Berl. Muench. Tieraerztl. Wsch., 113: 122

Open access
Safety of concomitant treatment with Non-Vitamin K Oral Anticoagulants and SSRI/SNRI antidepressants

, Mancuso A, Andò G, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018; 14:1057-1069. 5. Dexxience [EU]. BevyxXa [US] · Venous thromboemolism (VTE) prevention - first line - in at risk adult patients hospitalised for an acute medical illness [Cited 13.01.2019]. Accessible at: 6. Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants

Open access
Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?

, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30, 239–245, 1981. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 46, 1179–1187, 2006. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes

Open access
Adriamycin - efficacy and possible adverse effects

): 270-281. 8. Wcisło G., Korniluk J., Szarlej-Wcisło K., Pawlak W.Z., Nurzyński P., Duchnowska R.: Leczenie chorób nowotworowych czynnikiem martwicy nowotworów – alfa (TNF-alfa). Współczesna Onkologia, 2002; 4: 222–227. 9. Gabizon et al . Pharmacokinetics of Pegylated Liposomal Doxorubicin Review of Animal and Human Studies. Clin Pharmacokinet 2003; 42 (5): 419-436. 10. National Institute for Health and Clinical Excellence; TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydro-chloride and topotecan (review): Guidance

Open access
Adverse eff ects of polymeric nanoparticle poly(ethylene glycol)- block-polylactide methyl ether (PEG-b-PLA) on steroid hormone secretion by porcine granulosa cells

drug carriers. Adv Clin Exp Med 24, 749-758, 2015. Oberdoster G. Safety assessment for nanotechnology and nanomedicine: concept of nanotoxicology. J Intern Med 267, 89-105, 2009. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 163, 93-99, 2012. Pelham RW, Nix LC, Chavira RE, Cleveland MVB, Stetson P. Clinical trial: si ngle- and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in young and elderly subjects. Aliment

Open access